Skip to main content

BioNTech, Pfizer, J&J and Moderna Developing Omicron Vaccines

Adapted shot could be in use within 100 days, according to some reports.

Pharmaceutical giants are racing to adapt their existing COVID-19 vaccines or develop new ones to work against the omicron variant, which was identified in South Africa on November 24th. 

BioNTech  (BNTX) - Get Free Report, which partnered with Pfizer  (PFE) - Get Free Report on one of three COVID-19 vaccines currently approved for use in the U.S., is working to adapt its vaccine to address the omicron variant, according to Biopharmadive. The company is targeting development in six weeks with availability for use within 100 days, the report said. 

Moderna  (MRNA) - Get Free Report  and Johnson & Johnson  (JNJ) - Get Free Report, which make the two other U.S.-approved vaccines, are working on omicron-specific versions, according to the report. 

Additionally, Maryland-based Novavax  (NVAX) - Get Free Report plans to soon ask for U.S. approval of its shot.

On November 26th, the World Health Organization officially classified omicron as a "variant of concern.," sparking border closures and a sharp selloff in U.S. stocks.

On Monday, President Joe Biden called omicron a “a cause for concern, not a cause for panic," according to the New York Times, while outlining a strategy for combating the ongoing coronavirus outbreak with increased vaccinations, boosters and testing. U.S. shares rebounded sharply on Monday.

At the moment, health officials and experts say there is no conclusive evidence that omicron spreads quicker or is more harmful than previous variants. A key South African researcher said in an interview that symptoms appear to be milder, though that observation was based on younger patients. 

Shares of Moderna and BioNTech rose Monday, while Pfizer and Novavax both fell. Johnson & Johnson edged higher. 

Don’t miss our Cyber Monday 24-hour sale: Sign up for our Action Alerts PLUS investment club and get trading strategies and investing ideas from Real Money’s expert contributors for free.